Gerber A U, Brugger H P, Feller C, Stritzko T, Stalder B
J Infect Dis. 1986 Jan;153(1):90-7. doi: 10.1093/infdis/153.1.90.
An effort was made to elucidate the limits of drug-activity tests in small animals. Human plasma kinetics of gentamicin, netilmicin, ticarcillin, ceftazidime, and ceftriaxone were approximated in normal and in granulocytopenic mice infected with various strains of Pseudomonas aeruginosa in the thigh muscle or intraperitoneally. The effect of such dosing on bacterial time-kill curves and on survival was compared with the effect of identical amounts of drug given as a single-bolus injection. With beta-lactams, a highly significant superiority of fractionated dosing (simulated human kinetics) over bolus injections (murine plasma kinetics) was demonstrated, whereas with aminoglycosides it was a single-bolus injection that tended to be more active. Thus, when tested in conventional small-animal models, aminoglycoside activity may be overestimated, whereas beta-lactam activity may be underestimated in respect to humans. These differences found in vivo most probably reflect the different pharmacodynamics between aminoglycosides and beta-lactam drugs (time-kill curves, dose-response curves, and postantibiotic effect) similar to those previously observed in vitro.
人们致力于阐明小动物药物活性试验的局限性。在正常小鼠和粒细胞减少的小鼠中,通过大腿肌肉注射或腹腔注射感染各种铜绿假单胞菌菌株,模拟庆大霉素、奈替米星、替卡西林、头孢他啶和头孢曲松在人体中的血浆动力学。将这种给药方式对细菌时间杀灭曲线和生存率的影响与等量药物单次推注给药的效果进行比较。对于β-内酰胺类药物,分次给药(模拟人体动力学)相对于推注给药(小鼠血浆动力学)具有高度显著的优势,而对于氨基糖苷类药物,单次推注给药往往更具活性。因此,在传统的小动物模型中进行测试时,氨基糖苷类药物的活性可能被高估,而β-内酰胺类药物的活性相对于人类可能被低估。体内发现的这些差异很可能反映了氨基糖苷类药物和β-内酰胺类药物之间不同的药效学(时间杀灭曲线、剂量反应曲线和抗生素后效应),类似于之前在体外观察到的情况。